William Ho
President, Chief Executive Officer, Director & Co-founder IN8Bio
William Ho is Co-Founder, President, and Chief Executive Officer of IN8bio since its inception. Prior to the founding of IN8bio, from 2014 to 2017, William was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Prior to that, he was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio and served as its Public Investment Director from 2010 to 2014. Previously, William served as a Senior Equity Research Analyst at Bank of America from 2006 to 2009 and an Equity Research Analyst at Piper Jaffray & Co. from 2003 to 2006, covering the biotechnology and life-science tools sectors. Earlier in his career, William was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. William received an MBA from the University of Notre Dame and a B.S. in Biochemistry from McMaster University.
Seminars
- Discussing approaches to differentiate assets targeting competitive targets
- With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
- Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes
